Article Contents ::
- 1 The Brand Name RCIFAX Has Generic Salt :: RIFAXIMIN
- 2 RCIFAX Is From Company Lupin Priced :: Rs. 90
- 3 RCIFAX have RIFAXIMIN is comes under Sub class Miscellaneous of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name RCIFAX Has Generic Salt :: RIFAXIMIN
RCIFAX Is From Company Lupin Priced :: Rs. 90
RCIFAX have RIFAXIMIN is comes under Sub class Miscellaneous of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| RIFAXIMIN | TAB | Rs. 90 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| RCIFAX | Lupin | N.I. | 10 | Rs. 90 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Lupin :: RCIFAX | RIFAXIMIN | Anti Infectives | Miscellaneous |
Indications for Drugs ::
Traveler’s diarrhea, irritable bowel syndrome
Drug Dose ::
Traveler’s Diarrhea: For patients >12 years of age – 200 mg 3 times daily for 3 days. Hepatic Encephalopathy: For patients >18 years of age – 550 mg 2 times daily. Bacterial over growth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days. Renal Impairment: The pharmacokinetics of Rifaximin in patients with impaired renal function has not been studied. Hepatic Impairment: The systemic exposure of Rifaximin was markedly elevated in patients with hepatic impairment compared to healthy subjects.
Contraindication ::
Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product.
Drug Precautions ::
Rifaximin is not found to be effective in patients with diarrhea complicated by fever and/or blood in the stools. Rifaximin therapy should be discontinued if diarrhea symptoms get worse or persist for more than 24-48 hours and an alternative antibiotic therapy should be considered. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.
Drug Side Effects ::
Side effects include flatulence, headache, abdominal pain, rectal tenesmus, defecation urgency, nausea, constipation, pyrexia, vomiting. Reactions have been reported, including anaphylaxis, angioneurotic edema, and exfoliative dermatitis.
Pregnancy category ::
3
Drug Mode of Action ::
Antimicrobial action is a result of binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of transcription. Hepatic encephalopathy: Inhibits growth of enteric ammonia-producing bacteria to indirectly reduce serum ammonia level. Irritable bowel syndrome with diarrhea (off-label): Inhibits growth of enteric bacteria to reduce gas production.
Drug Interactions ::
Although in vitro studies demonstrated the potential of rifaximin to interact with cytochrome P450 (CYP3A4), a clinical drug-drug interaction study demonstrated that rifaximin did not significantly affect the pharmacokinetics of midazolam. An additional clinical drug-drug interaction study showed no effect of rifaximin on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and norgestimate. Therefore, clinical interactions with drugs metabolized by human cytochrome P450 isozymes are not expected.
